Vaginal microbicides and their delivery platforms
Authors:
- 8 February 2014
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Drug Delivery
- Vol. 11 (5) , 723-740
Abstract
HIV type 1 infection, despite having fallen by one-third over the past decade, remains a global health concern affecting millions of individuals worldwide. A focal point in contemporary research aimed at global HIV prevention has been the development of safe and efficacious coitally dependent and coitally independent anti-HIV microbicides to curb heterosexual HIV transmission. Despite extensive research efforts to develop novel vaginal antiretroviral (ARV) formulations and intravaginal ring delivery systems, the clinical advancement of microbicides with improved safety, efficacy and tolerability has significantly lagged behind. This review focuses on the current status of both coitally dependent and coitally independent delivery platforms designed to increase user acceptability and clinical effectiveness of anti-HIV microbicides. The clinical failure of several vaginal microbicide candidates has propelled the field to mechanism-based ARV candidates that act more specifically on viral receptors, viral enzymes and host proteins. Consequently, improved vaginal microbicide delivery strategies that achieve uniform drug distribution with enhanced solubility, sustained drug release, improved product adherence with reduced dosing frequency and lack of effect on the vaginal mucosa and microbiota are being sought. Clinical success with vaginal microbicides may best be achieved through the combined effects of ARV compounds that exhibit different mechanisms of action with potent activity against multidrug-resistant HIV and efficacious delivery systems.Keywords
This publication has 78 references indexed in Scilit:
- Broad neutralization coverage of HIV by multiple highly potent antibodiesNature, 2011
- Cell‐Free HIV‐1 Virucidal Action by Modified Peptide Triazole Inhibitors of Env gp120ChemMedChem, 2011
- Tenofovir renal proximal tubular toxicity is regulated By OAT1 and MRP4 transportersLaboratory Investigation, 2011
- Tenofovir renal toxicity targets mitochondria of renal proximal tubulesLaboratory Investigation, 2009
- Novel Dual Inhibitory Function Aptamer–siRNA Delivery System for HIV-1 TherapyMolecular Therapy, 2008
- T Cell-Specific siRNA Delivery Suppresses HIV-1 Infection in Humanized MiceCell, 2008
- Setting the stage: host invasion by HIVNature Reviews Immunology, 2008
- Rational design of novel HIV-1 entry inhibitors by RANTES engineeringVaccine, 2008
- Inhibition of HIV Fusion with Multivalent Gold NanoparticlesJournal of the American Chemical Society, 2008
- RNAi therapeutics: Principles, prospects and challengesAdvanced Drug Delivery Reviews, 2007